GVAX cancer vaccine consisting of patient tumor cells engineered to secrete G-CSF data

SOMA announced that results of Phase I/II testing in 50 patients showed safety and a specific

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE